Half-year report · Q2
4574.TEDINET S100WI6C
Period2025-01-01 → 2025-06-30
Filed2025-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥6.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | ¥482m | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥688m | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥528m | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥724m | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥898m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥12.9bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥13.4bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.7bn | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥4.9bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥8.1bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.2bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥362m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥256m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥135m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥562m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.9 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.24 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
| Otherother segments | revenue | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | segment profit | 2024-01-01 → 2024-06-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥401m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥195m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-06-30 | ¥884m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 523
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1QuarterInstant | 4916000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4139000000 | JPY |
| Write downs of inventories | Prior1YTDDuration | -0 | JPY |
| Write downs of inventories | CurrentYTDDuration | -10000000 | JPY |
| Advertising expenses sga | Prior1YTDDuration | 58000000 | JPY |
| Advertising expenses sga | CurrentYTDDuration | 183000000 | JPY |
| Payroll and allowances sga | Prior1YTDDuration | 390000000 | JPY |
| Payroll and allowances sga | CurrentYTDDuration | 350000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 29000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 28000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 27000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 32000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2654000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | 203000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2860000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 2860000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2654000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | 203000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2860000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 2860000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 1086000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | -195000000 | JPY |
| Operating income | Prior1YTDDuration_OtherReportableSegmentsMember | -6000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 884000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -401000000 | JPY |
| Operating income | Prior1YTDDuration | 482000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2206000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | 203000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2412000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 2412000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2206000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | 203000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |